Q-omics provides the consensus-scored HNRNPR profile across patient tissues and cancer cell-line models. HNRNPR expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, HNRNPR is differentially expressed in 13, with the highest sampling consensus in HNSC. Additionally, HNRNPR protein abundance shows 29,019 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight ACC, HNSC, and GBM as cancer lineages where HNRNPR shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for HNRNPR — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes HNRNPR survival associations across molecular data types. HNRNPR RNA expression shows survival associations in the most cancer types (22), followed by mutation status (5) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible HNRNPR RNA expression–survival associations across cancer types. High HNRNPR expression shows unfavorable associations in ACC, LIHC, KIRP and SARC, but favorable associations in KIRC and UCS. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for HNRNPR RNA expression.
This table summarizes HNRNPR tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 5. The strongest signals are observed in HNSC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for HNRNPR. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. HNRNPR shows lower tumor expression in THCA and higher tumor expression in HNSC, BLCA, LIHC, STAD and LUSC. The HNSC box plot shows higher HNRNPR RNA expression in tumor versus normal tissue (log2 FC = +0.794, t-test p < 0.001).
This table shows molecular features associated with HNRNPR in patient tissues and cancer cell lines. In patient samples, HNRNPR shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, HNRNPR RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in OVARY and BLOOD_Leukemia.
